{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T10:58:23Z","timestamp":1793271503285,"version":"4.5.0"},"reference-count":90,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T00:00:00Z","timestamp":1582243200000},"content-version":"unspecified","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2020,1,31]]},"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Biologic disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs are used in patients with psoriatic arthritis (PsA), but few studies directly compare their clinical efficacy. In such situations, network meta-analysis (NMA) can inform evidence-based decision-making.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To evaluate the comparative efficacy and safety of approved bDMARDs in patients with PsA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Bayesian NMA was conducted to compare the clinical efficacy of bDMARDs at weeks 12\u201216 in bDMARD-na\u00efve patients with PsA in terms of American College of Rheumatology (ACR) criteria, Psoriatic Arthritis Response Criteria (PsARC) and Psoriasis Area and Severity Index (PASI). Safety end points were evaluated in the overall mixed population of bDMARD-naive and bDMARD-experienced patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>For ACR, all treatments except abatacept were statistically superior to placebo. Infliximab was most effective, followed by golimumab and etanercept, which were statistically superior to most other treatments. Ixekizumab 80\u2009mg every 2 weeks (Q2W) was statistically superior to abatacept subcutaneous, apremilast and both regimens of ustekinumab; similar findings were observed for ixekizumab 80\u2009mg Q4W. For PsARC response, ixekizumab did not significantly differ from other therapies, except for golimumab, infliximab and etanercept, which were superior to most other agents including ixekizumab. For PASI response, infliximab was numerically most effective, but was not statistically superior to ixekizumab, which was the next best performing agent. Analysis of safety end points identified few differences between treatments.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our NMA confirms the efficacy and acceptable safety profile of bDMARDs in patients with active PsA. There were generally few statistically significant differences between most treatments.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2019-001117","type":"journal-article","created":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T05:05:15Z","timestamp":1582520715000},"page":"e001117","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":80,"title":["Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis"],"prefix":"10.1136","volume":"6","author":[{"given":"Adeline","family":"Ruyssen-Witrand","sequence":"first","affiliation":[{"name":"Rheumatology Center, Purpan Teaching Hospital, Toulouse, France"},{"name":"Rheumatology Center, UMR 1027, Inserm, Paul Sabatier University Toulouse III, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Perry","sequence":"additional","affiliation":[{"name":"Value Demonstration and Communication, Adelphi Values, Bollington, Cheshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Watkins","sequence":"additional","affiliation":[{"name":"Statistical Consultancy, Clarostat Consulting Ltd, Alderley Edge, Cheshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Braileanu","sequence":"additional","affiliation":[{"name":"Value Demonstration and Communication, Adelphi Values, Bollington, Cheshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayathri","family":"Kumar","sequence":"additional","affiliation":[{"name":"Health Economics & Pricing, Reimbursement and Access, Eli Lilly and Company Ltd, Basingstoke, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Kiri","sequence":"additional","affiliation":[{"name":"Health Outcomes and Health Technology Assessment, Eli Lilly and Company Ltd, Basingstoke, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debby","family":"Nott","sequence":"additional","affiliation":[{"name":"Health Outcomes and Health Technology Assessment, Eli Lilly and Company Ltd, Basingstoke, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyi","family":"Liu-Leage","sequence":"additional","affiliation":[{"name":"International Business Unit\u2014Rheumatology, Lilly France, Neuilly-sur-Seine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Hartz","sequence":"additional","affiliation":[{"name":"Global Patient Outcomes and Real World Evidence International, Eli Lilly and Company, Windlesham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Sapin","sequence":"additional","affiliation":[{"name":"European Statistics, Lilly France, Neuilly-sur-Seine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,2,23]]},"reference":[{"key":"2025090312454470000_6.1.e001117.1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s12016-017-8630-7","article-title":"Clinical features of psoriatic arthritis: a comprehensive review of unmet clinical needs","volume":"55","author":"McArdle","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"2025090312454470000_6.1.e001117.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"2025090312454470000_6.1.e001117.3","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0618-5"},{"key":"2025090312454470000_6.1.e001117.4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1586\/14737167.2015.965154","article-title":"The indirect costs of psoriatic arthritis: systematic review and meta-analysis","volume":"15","author":"Kawalec","year":"2015","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2025090312454470000_6.1.e001117.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215386"},{"key":"2025090312454470000_6.1.e001117.6","doi-asserted-by":"crossref","DOI":"10.1186\/1741-7015-9-79","article-title":"Network meta-analysis-highly attractive but more methodological research is needed","volume":"9","author":"Li","year":"2011","journal-title":"BMC Med"},{"key":"2025090312454470000_6.1.e001117.7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.331.7521.897"},{"key":"2025090312454470000_6.1.e001117.8","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200826090-00006"},{"key":"2025090312454470000_6.1.e001117.9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta9260","article-title":"Indirect comparisons of competing interventions","volume":"9","author":"Glenny","year":"2005","journal-title":"Health Technol Assess"},{"key":"2025090312454470000_6.1.e001117.10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00296-017-3919-7","article-title":"Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis","volume":"38","author":"Kawalec","year":"2018","journal-title":"Rheumatol Int"},{"key":"2025090312454470000_6.1.e001117.11","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2217\/cer-2018-0075","article-title":"Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics\/apremilast: a network meta-analysis","volume":"7","author":"McInnes","year":"2018","journal-title":"J Comp Eff Res"},{"key":"2025090312454470000_6.1.e001117.12","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/rheumatology\/kex452","article-title":"Efficacy and safety of biologics targeting interleukin-6, -12\/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis","volume":"57","author":"Wu","year":"2018","journal-title":"Rheumatology"},{"key":"2025090312454470000_6.1.e001117.13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/RHU.0000000000000583","article-title":"A systematic review and meta-analysis of efficacy and safety of novel interleukin inhibitors in the management of psoriatic arthritis","volume":"24","author":"Bilal","year":"2018","journal-title":"J Clin Rheumatol"},{"key":"2025090312454470000_6.1.e001117.14","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1159\/000484520","article-title":"Th17 inhibitors in active psoriatic arthritis: a systematic review and meta-analysis of randomized controlled clinical trials","volume":"233","author":"Naik","year":"2017","journal-title":"Dermatology"},{"key":"2025090312454470000_6.1.e001117.15","unstructured":"European medicines agency: ixekizumab (Taltz\u00ae) summary of product characteristics. Available: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003943\/WC500205804.pdf [Accessed 23 Nov 2018]."},{"key":"2025090312454470000_6.1.e001117.16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analysis: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"2025090312454470000_6.1.e001117.17","unstructured":"Higgins JPT , Green S . Cochrane Handbook for systematic reviews of interventions, version 5.1.0. Available: www.handbook.cochrane.org [Accessed Mar 2011]."},{"key":"2025090312454470000_6.1.e001117.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.22552"},{"key":"2025090312454470000_6.1.e001117.19","doi-asserted-by":"crossref","first-page":"ii49","DOI":"10.1136\/ard.2004.034165","article-title":"Psoriatic arthritis assessment tools in clinical trials","volume":"64 Suppl 2","author":"Mease","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2025090312454470000_6.1.e001117.20","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.051706"},{"key":"2025090312454470000_6.1.e001117.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.09.014"},{"key":"2025090312454470000_6.1.e001117.22","unstructured":"National Institute for Health and Care Excellence (NICE) . Methods for development of NICE public health guidance, 2012. Available: https:\/\/www.nice.org.uk\/process\/pmg4\/chapter\/introduction [Accessed 23 Nov 2018]."},{"key":"2025090312454470000_6.1.e001117.23","unstructured":"Dias S , Welton NJ , Sutton AJ , et al . NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. 2011. (technical support document in evidence synthesis; TSD2) 2011."},{"key":"2025090312454470000_6.1.e001117.24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jaut.2016.10.009","article-title":"Management of psoriatic arthritis: early diagnosis, monitoring of disease severity and cutting edge therapies","volume":"76","author":"Raychaudhuri","year":"2017","journal-title":"J Autoimmun"},{"key":"2025090312454470000_6.1.e001117.25","unstructured":"Jancin B . Is PASI 100 the new benchmark in psoriasis? conference coverage of the 42nd annual Hawaii dermatology seminar, February 2018. rheumatology news April 24, 2018. Available: https:\/\/www.mdedge.com\/rheumatology\/article\/164091\/psoriasis\/pasi-100-new-benchmark-psoriasis [Accessed 22 Jul 2019]."},{"key":"2025090312454470000_6.1.e001117.26","unstructured":"Dias S , Sutton AJ , Welton NJ , et al . NICE DSU technical support document 3: heterogeneity: subgroups, meta-regression, bias and bias-adjustment, 2012. Available: http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2016\/03\/TSD3-Heterogeneity.final-report.08.05.12.pdf [Accessed 10 Dec 2018]."},{"key":"2025090312454470000_6.1.e001117.27","doi-asserted-by":"publisher","DOI":"10.3310\/hta21410"},{"key":"2025090312454470000_6.1.e001117.28","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00393-017-0355-8","article-title":"Relative efficacy and safety of apremilast, secukinumab, and ustekinumab for the treatment of psoriatic arthritis","volume":"77","author":"Song","year":"2018","journal-title":"Zeitschrift f\u00fcr Rheumatologie"},{"key":"2025090312454470000_6.1.e001117.29","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2147\/PPA.S128665","article-title":"Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis","volume":"11","author":"Svedbom","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"2025090312454470000_6.1.e001117.30","first-page":"681","article-title":"Treatment modifying factors of biologics for psoriatic arthritis: a systematic review and Bayesian meta-regression","volume":"35","author":"Druyts","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312454470000_6.1.e001117.31","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (future 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"The Lancet"},{"key":"2025090312454470000_6.1.e001117.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.04.002"},{"key":"2025090312454470000_6.1.e001117.33","unstructured":"Nash P , Ohson K , Walsh JDN , et al . Early onset of efficacy with apremilast monotherapy in biologic-naive patients with active psoriatic arthritis: a phase IIIb, randomized, controlled trial [abstract]. Arthritis Rheum 2016;68."},{"key":"2025090312454470000_6.1.e001117.34","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2017-eular.3021","article-title":"OP0219\u2005early onset of efficacy with apremilast monotherapy in biologic-naive patients with active psoriatic arthritis: a phase 3b, randomized, controlled trial","volume":"76","author":"Nash","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025090312454470000_6.1.e001117.35","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211568"},{"key":"2025090312454470000_6.1.e001117.36","doi-asserted-by":"publisher","DOI":"10.1002\/art.21306"},{"key":"2025090312454470000_6.1.e001117.37","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092767"},{"key":"2025090312454470000_6.1.e001117.38","unstructured":"National Institute for Health and Care Excellence . Final appraisal determination - Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs. Available: https:\/\/www.nice.org.uk\/guidance\/ta445\/documents\/final-appraisal-determination-document [Accessed Oct 2017]."},{"key":"2025090312454470000_6.1.e001117.39","unstructured":"Mease P , Gottlieb A , van der Heijde D , et al . Abatacept in the treatment of active psoriatic arthritis: 24-week results from a Phase III study [abstract]. Arthritis Rheumatol 2016;68."},{"key":"2025090312454470000_6.1.e001117.40","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210724"},{"key":"2025090312454470000_6.1.e001117.41","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1136\/annrheumdis-2015-eular.2178","article-title":"THU0411\u2005Secukinumab efficacy in anti-TNF-naive and anti-TNF-IR patients with psoriatic arthritis: results of a phase 3 multicenter, double-blind, placebo-controlled study (Future 2)","volume":"74","author":"Kavanaugh","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025090312454470000_6.1.e001117.42","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160275"},{"key":"2025090312454470000_6.1.e001117.43","doi-asserted-by":"crossref","first-page":"351.1","DOI":"10.1136\/annrheumdis-2015-eular.2276","article-title":"THU0421\u2005Secukinumab is effective in reducing dactylitis and enthesitis using multiple measures in patients with psoriatic arthritis: data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study (Future 2)","volume":"74","author":"Kirkham","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025090312454470000_6.1.e001117.44","doi-asserted-by":"crossref","first-page":"A226","DOI":"10.1016\/j.jval.2016.03.1167","article-title":"Psoriatic arthritis response criteria scores: results from a placebo-response adjusted network meta-analysis with secukinumab","volume":"19","author":"Thom","year":"2016","journal-title":"Value in Health"},{"key":"2025090312454470000_6.1.e001117.45","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13075-018-1551-x","article-title":"Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (future 3)","volume":"20","author":"Nash","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2025090312454470000_6.1.e001117.46","first-page":"S1","article-title":"Arthritis: primary results through 52 weeks from a phase-3 randomized placebo-controlled study (future 4)","volume":"24","author":"Kivitz","year":"2018","journal-title":"J Clin Rheumatol"},{"key":"2025090312454470000_6.1.e001117.47","unstructured":"Mease PJ , van der Heijde D , Landew\u00e9 RBM , et al . Subcutaneous secukinumab inhibits radiographic progression in psoriatic arthritis: primary results from a large randomized, controlled, double-blind phase 3 study [abstract]. Arthritis Rheumatol 2017;69."},{"key":"2025090312454470000_6.1.e001117.48","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212687"},{"key":"2025090312454470000_6.1.e001117.49","first-page":"1040","article-title":"Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy","volume":"34","author":"Genovese","year":"2007","journal-title":"J Rheumatol"},{"key":"2025090312454470000_6.1.e001117.50","doi-asserted-by":"publisher","DOI":"10.1002\/art.24403"},{"key":"2025090312454470000_6.1.e001117.51","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1002\/acr.22044","article-title":"Patient-Reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial","volume":"65","author":"Kavanaugh","year":"2013","journal-title":"Arthritis Care Res"},{"key":"2025090312454470000_6.1.e001117.52","doi-asserted-by":"publisher","DOI":"10.1002\/art.20967"},{"key":"2025090312454470000_6.1.e001117.53","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032268"},{"key":"2025090312454470000_6.1.e001117.54","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.040196"},{"key":"2025090312454470000_6.1.e001117.55","first-page":"958","article-title":"Safety and efficacy of ABT-122, a TNF and IL-17\u2013targeted dual variable domain (DVD)\u2013Ig\u2122, in psoriatic arthritis patients with inadequate response to methotrexate: results from a phase 2 trial","volume":"68","author":"Mease","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090312454470000_6.1.e001117.56","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/art.40579","article-title":"Phase 2 study of ABT-122, a TNF- and IL-17A-Targeted dual variable domain immunoglobulin, in psoriatic arthritis with inadequate methotrexate response","volume":"70","author":"Mease","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025090312454470000_6.1.e001117.57","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"The Lancet"},{"key":"2025090312454470000_6.1.e001117.58","doi-asserted-by":"publisher","DOI":"10.1002\/art.20335"},{"key":"2025090312454470000_6.1.e001117.59","doi-asserted-by":"publisher","DOI":"10.1002\/art.30176"},{"key":"2025090312454470000_6.1.e001117.60","first-page":"4371","article-title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumor necrosis factor inhibitors: OPAL beyond, a randomized, double blind, placebo-controlled, phase 3 trial","volume":"68","author":"Gladman","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090312454470000_6.1.e001117.61","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"key":"2025090312454470000_6.1.e001117.62","unstructured":"Helliwell PS , Coates LC , Gerald OF , et al . Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis. Arthritis Rheumatol 2017;69."},{"key":"2025090312454470000_6.1.e001117.63","unstructured":"Mease P , Hall S , FitzGerald O , et al . Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, or adalimumab in patients with active psoriatic arthritis and an inadequate response to conventional synthetic DMARDs: a randomized, placebo-controlled, phase 3 trial [abstract]. Arthritis Rheumatol 2016;68."},{"key":"2025090312454470000_6.1.e001117.64","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/annrheumdis-2017-eular.1416","article-title":"OP0216\u2005efficacy and safety of tofacitinib, an oral janus kinase inhibitor, or adalimumab in patients with active psoriatic arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (CSDMARDS): a randomised, placebo-controlled, phase 3 trial","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025090312454470000_6.1.e001117.65","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"key":"2025090312454470000_6.1.e001117.66","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/annrheumdis-2014-eular.1827","article-title":"OP0078\u2005Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in measures of disease activity in patients with psoriatic arthritis: results from 3 phase 3, randomized, controlled trials","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2025090312454470000_6.1.e001117.67","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205056"},{"key":"2025090312454470000_6.1.e001117.68","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140647"},{"key":"2025090312454470000_6.1.e001117.69","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151376"},{"key":"2025090312454470000_6.1.e001117.70","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207963"},{"key":"2025090312454470000_6.1.e001117.71","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"The Lancet"},{"key":"2025090312454470000_6.1.e001117.72","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22645"},{"key":"2025090312454470000_6.1.e001117.73","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204655"},{"key":"2025090312454470000_6.1.e001117.74","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203696"},{"key":"2025090312454470000_6.1.e001117.75","doi-asserted-by":"crossref","first-page":"A594","DOI":"10.1016\/j.jval.2016.09.1426","article-title":"Certolizumab pegol is associated with long-term improvements in patient-reported outcomes in psoriatic arthritis: 4-year outcomes from the Rapid-Psa study","volume":"19","author":"Gladman","year":"2016","journal-title":"Value in Health"},{"key":"2025090312454470000_6.1.e001117.76","unstructured":"Khraishi M , Gottlieb AB , Hoepken B , et al . The effect of certolizumab pegol on skin manifestations of psoriatic arthritis over 4 years of treatment [abstract]. Arthritis Rheumatol 2016;68."},{"key":"2025090312454470000_6.1.e001117.77","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000119","article-title":"Effect of certolizumab pegol over 96\u2005weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure","volume":"1","author":"Mease","year":"2015","journal-title":"RMD Open"},{"key":"2025090312454470000_6.1.e001117.78","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2016-eular.3205","article-title":"FRI0472\u2005improvements in joint outcomes of psoriatic arthritis over 4 years of treatment with certolizumab pegol in patients with and without prior anti-TNF exposure","volume":"75","author":"Mease","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025090312454470000_6.1.e001117.79","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1136\/annrheumdis-2016-eular.1399","article-title":"THU0441\u2005Effect of Concomitant Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) on The Efficacy and Safety of Ixekizumab in Biologic Dmard-Naive Patients with Active Psoriatic Arthritis","volume":"75","author":"Coates","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025090312454470000_6.1.e001117.80","unstructured":"Gottlieb AB , Coates LC , Shuler CL , et al . Effect of concomitant conventional disease-modifying antirheumatic drugs (DMARDs) on the efficacy and safety of ixekizumab in biologic DMARD-naive patients with active psoriatic arthritis. Arthritis Rheumatol 2016;68."},{"key":"2025090312454470000_6.1.e001117.81","unstructured":"Lilly I1F-MC-RHAP Clinical Study Report . A multicenter, randomized, double-blind, active and placebo-controlled 24-week study followed by long term evaluation of efficacy and safety of ixekizumab (LY2439821) in biologic disease-modifying antirheumatic drug-naive patients with active psoriatic arthritis 2016."},{"key":"2025090312454470000_6.1.e001117.82","first-page":"1277","article-title":"A randomized, double-blind, active-and placebo-controlled phase 3 study of efficacy and safety of ixekizumab, adalimumab, and placebo therapy in patients na\u00efve to biologic disease modifying anti-rheumatic drugs with active psoriatic arthritis","volume":"67","author":"Mease","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025090312454470000_6.1.e001117.83","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"2025090312454470000_6.1.e001117.84","unstructured":"Thaci D , Morita A , Birt J , et al . Association of early skin improvement with ACR responses among biologic DMARD-naive psoriatic arthritic patients treated with ixekizumab [abstract]. Arthritis Rheumatol 2016;68."},{"key":"2025090312454470000_6.1.e001117.85","unstructured":"ClinicalTrials.gov . A multicenter, randomized, double-blind, placebo controlled 24-week study followed by long term evaluation of efficacy and safety of ixekizumab (LY2439821) in biologic disease-modifying antirheumatic drug-experienced patients with active psoriatic arthritis 2015."},{"key":"2025090312454470000_6.1.e001117.86","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/annrheumdis-2017-eular.3105","article-title":"SAT0437 ixekizumab improves nail and skin lesions in patients with active psoriatic arthritis and prior TNF inadequate response","volume":"76","author":"Kristensen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025090312454470000_6.1.e001117.87","unstructured":"Lilly I1F-MC-RHBE Clinical Study Report . A multicenter, randomized, double-blind, placebo controlled 24-week study followed by long term evaluation of efficacy and safety of ixekizumab (LY2439821) in biologic disease-modifying antirheumatic drug-experienced patients with active psoriatic arthritis 2016."},{"key":"2025090312454470000_6.1.e001117.88","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/annrheumdis-2017-eular.1576","article-title":"OP0201\u2005A phase 3 study of the efficacy and safety of ixekizumab in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitor(s)","volume":"76","author":"Nash","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025090312454470000_6.1.e001117.89","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"The Lancet"},{"key":"2025090312454470000_6.1.e001117.90","article-title":"FRI0502\u2005Ixekizumab reduces disease activity in active psoriatic arthritis patients who had previous inadequate response to tumour necrosis factor-inhibitors","volume":"76","author":"Coates","year":"2017","journal-title":"Ann Rheum Dis"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2019-001117","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:46:02Z","timestamp":1756928762000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2019-001117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,2,23]]},"published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1136\/rmdopen-2019-001117"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2019-001117","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2]]}}}